Which has preferable valuation and earnings, SYRE or BIIB?

Biogen has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics $890K 8,952.09 -$155.20M -$1.95 N/A Biogen $9.89B 3.24 $1.29B $5.65 38.43

Does the media favor SYRE or BIIB?

In the previous week, Spyre Therapeutics had 8 more articles in the media than Biogen. MarketBeat recorded 17 mentions for Spyre Therapeutics and 9 mentions for Biogen. Biogen's average media sentiment score of 1.23 beat Spyre Therapeutics' score of 0.68 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ROIV or SYRE?

In the previous week, Roivant Sciences had 20 more articles in the media than Spyre Therapeutics. MarketBeat recorded 37 mentions for Roivant Sciences and 17 mentions for Spyre Therapeutics. Roivant Sciences' average media sentiment score of 0.70 beat Spyre Therapeutics' score of 0.68 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 13 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or INSM more profitable?

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Spyre Therapeutics' return on equity of -30.74% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Insmed -76.94% -123.94% -44.30%

Does the media favor SYRE or INSM?

In the previous week, Spyre Therapeutics had 7 more articles in the media than Insmed. MarketBeat recorded 17 mentions for Spyre Therapeutics and 10 mentions for Insmed. Insmed's average media sentiment score of 1.23 beat Spyre Therapeutics' score of 0.68 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SYRE or INCY?

Incyte has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics $890K 8,952.09 -$155.20M -$1.95 N/A Incyte $5.14B 4.79 $1.29B $7.85 15.47

Is SYRE or INCY more profitable?

Incyte has a net margin of 27.71% compared to Spyre Therapeutics' net margin of 0.00%. Incyte's return on equity of 29.93% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Incyte 27.71% 29.93% 22.88%

Does the media refer more to SYRE or INCY?

In the previous week, Incyte had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 19 mentions for Incyte and 17 mentions for Spyre Therapeutics. Incyte's average media sentiment score of 0.85 beat Spyre Therapeutics' score of 0.68 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SYRE or BNTX?

In the previous week, BioNTech had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 20 mentions for BioNTech and 17 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.68 beat BioNTech's score of 0.46 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 10 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Spyre Therapeutics (SYRE) Competitors

$90.60 +1.89 (+2.13%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$90.68 +0.08 (+0.08%)

As of 09/11/2026 07:30 PM Eastern

Compare

SYRE vs. BIIB, ROIV, INSM, INCY, and BNTX

Should you buy Spyre Therapeutics stock or one of its competitors? Spyre Therapeutics's main competitors and comparable companies include Biogen (BIIB), Roivant Sciences (ROIV), Insmed (INSM), Incyte (INCY), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Spyre Therapeutics compare to Biogen?

Spyre Therapeutics (NASDAQ:SYRE) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Biogen has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,952.09	-$155.20M	-$1.95	N/A
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43

Biogen has a net margin of 8.32% compared to Spyre Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Biogen	8.32%	11.18%	6.88%

Spyre Therapeutics currently has a consensus target price of $109.69, indicating a potential upside of 21.07%. Biogen has a consensus target price of $230.14, indicating a potential upside of 5.98%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Spyre Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Spyre Therapeutics has a beta of 2.99, suggesting that its share price is 199% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

In the previous week, Spyre Therapeutics had 8 more articles in the media than Biogen. MarketBeat recorded 17 mentions for Spyre Therapeutics and 9 mentions for Biogen. Biogen's average media sentiment score of 1.23 beat Spyre Therapeutics' score of 0.68 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	6 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats Spyre Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Roivant Sciences had 20 more articles in the media than Spyre Therapeutics. MarketBeat recorded 37 mentions for Roivant Sciences and 17 mentions for Spyre Therapeutics. Roivant Sciences' average media sentiment score of 0.70 beat Spyre Therapeutics' score of 0.68 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	13 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences presently has a consensus target price of $40.63, suggesting a potential downside of 0.48%. Spyre Therapeutics has a consensus target price of $109.69, suggesting a potential upside of 21.07%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spyre Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 2.99, indicating that its share price is 199% more volatile than the broader market.

Spyre Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,569.62	-$299.77M	-$0.53	N/A
Spyre Therapeutics	$890K	8,952.09	-$155.20M	-$1.95	N/A

Spyre Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Summary

Spyre Therapeutics beats Roivant Sciences on 10 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Insmed?

Spyre Therapeutics (NASDAQ:SYRE) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Spyre Therapeutics has a beta of 2.99, meaning that its share price is 199% more volatile than the broader market. Comparatively, Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

Spyre Therapeutics has higher earnings, but lower revenue than Insmed. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,952.09	-$155.20M	-$1.95	N/A
Insmed	$606.42M	46.60	-$1.28B	-$4.11	N/A

In the previous week, Spyre Therapeutics had 7 more articles in the media than Insmed. MarketBeat recorded 17 mentions for Spyre Therapeutics and 10 mentions for Insmed. Insmed's average media sentiment score of 1.23 beat Spyre Therapeutics' score of 0.68 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Spyre Therapeutics' return on equity of -30.74% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Insmed	-76.94%	-123.94%	-44.30%

Spyre Therapeutics presently has a consensus price target of $109.69, suggesting a potential upside of 21.07%. Insmed has a consensus price target of $205.52, suggesting a potential upside of 58.81%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Spyre Therapeutics beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Spyre Therapeutics compare to Incyte?

Spyre Therapeutics (NASDAQ:SYRE) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Incyte has a net margin of 27.71% compared to Spyre Therapeutics' net margin of 0.00%. Incyte's return on equity of 29.93% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Incyte	27.71%	29.93%	22.88%

Spyre Therapeutics presently has a consensus price target of $109.69, indicating a potential upside of 21.07%. Incyte has a consensus price target of $124.05, indicating a potential upside of 2.12%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Spyre Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Spyre Therapeutics has a beta of 2.99, suggesting that its share price is 199% more volatile than the broader market. Comparatively, Incyte has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Incyte has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,952.09	-$155.20M	-$1.95	N/A
Incyte	$5.14B	4.79	$1.29B	$7.85	15.47

In the previous week, Incyte had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 19 mentions for Incyte and 17 mentions for Spyre Therapeutics. Incyte's average media sentiment score of 0.85 beat Spyre Therapeutics' score of 0.68 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Incyte beats Spyre Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to BioNTech?

Spyre Therapeutics (NASDAQ:SYRE) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Spyre Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
BioNTech	-63.54%	-6.86%	-6.00%

Spyre Therapeutics currently has a consensus price target of $109.69, suggesting a potential upside of 21.07%. BioNTech has a consensus price target of $126.00, suggesting a potential upside of 30.26%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

Spyre Therapeutics has a beta of 2.99, suggesting that its share price is 199% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

In the previous week, BioNTech had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 20 mentions for BioNTech and 17 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.68 beat BioNTech's score of 0.46 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	10 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Spyre Therapeutics has higher earnings, but lower revenue than BioNTech. Spyre Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,952.09	-$155.20M	-$1.95	N/A
BioNTech	$3.25B	7.54	-$1.29B	-$7.83	N/A

Summary

Spyre Therapeutics beats BioNTech on 8 of the 15 factors compared between the two stocks.

Get Spyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRE vs. The Competition

Export

Metric	Spyre Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.97B	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-46.46	8.41	214.39	20.85
Price / Sales	8,952.09	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	12.57	15.12	10.33	6.21
Net Income	-$155.20M	-$22.86M	$3.50B	$358.54M
7 Day Performance	1.82%	-4.34%	-3.32%	-2.35%
1 Month Performance	-11.05%	0.54%	-0.53%	-3.23%
1 Year Performance	478.91%	40.74%	23.51%	8.79%

Spyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRE Spyre Therapeutics	2.4177 of 5 stars	$90.60 +2.1%	$109.69 +21.1%	+478.9%	$7.97B	$890K	N/A	112	Analyst Forecast Gap Down
BIIB Biogen	3.2945 of 5 stars	$212.50 -3.8%	$228.50 +7.5%	+49.9%	$31.40B	$9.89B	37.61	7,500	Positive News Analyst Forecast
ROIV Roivant Sciences	1.509 of 5 stars	$41.48 +18.8%	$37.68 -9.2%	+189.9%	$29.96B	$8.26M	N/A	860	News Coverage Analyst Forecast Options Volume Gap Down High Trading Volume
INSM Insmed	3.4375 of 5 stars	$124.89 -1.1%	$205.52 +64.6%	-11.3%	$27.27B	$606.42M	N/A	1,664	News Coverage Positive News Insider Trade
INCY Incyte	3.3104 of 5 stars	$124.40 -1.9%	$124.05 -0.3%	+46.2%	$25.22B	$5.14B	15.85	2,844	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRE) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyre Therapeutics (SYRE) Competitors

SYRE vs. BIIB, ROIV, INSM, INCY, and BNTX

How does Spyre Therapeutics compare to Biogen?

Summary

How does Spyre Therapeutics compare to Roivant Sciences?

Summary

How does Spyre Therapeutics compare to Insmed?

Summary

How does Spyre Therapeutics compare to Incyte?

Summary

How does Spyre Therapeutics compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyre Therapeutics (SYRE) Competitors

SYRE vs. BIIB, ROIV, INSM, INCY, and BNTX

How does Spyre Therapeutics compare to Biogen?

Which has preferable valuation and earnings, SYRE or BIIB?

Is SYRE or BIIB more profitable?

Do analysts prefer SYRE or BIIB?

Do institutionals and insiders have more ownership in SYRE or BIIB?

Which has more volatility & risk, SYRE or BIIB?

Does the media favor SYRE or BIIB?

Summary

How does Spyre Therapeutics compare to Roivant Sciences?

Do insiders & institutionals believe in ROIV or SYRE?

Does the media refer more to ROIV or SYRE?

Do analysts recommend ROIV or SYRE?

Which has more volatility & risk, ROIV or SYRE?

Which has better valuation & earnings, ROIV or SYRE?

Is ROIV or SYRE more profitable?

Summary

How does Spyre Therapeutics compare to Insmed?

Which has more volatility and risk, SYRE or INSM?

Which has better valuation & earnings, SYRE or INSM?

Does the media favor SYRE or INSM?

Do insiders and institutionals hold more shares of SYRE or INSM?

Is SYRE or INSM more profitable?

Do analysts recommend SYRE or INSM?

Summary

How does Spyre Therapeutics compare to Incyte?

Is SYRE or INCY more profitable?

Do analysts recommend SYRE or INCY?

Do institutionals & insiders have more ownership in SYRE or INCY?

Which has more risk & volatility, SYRE or INCY?

Which has stronger earnings and valuation, SYRE or INCY?

Does the media refer more to SYRE or INCY?

Summary

How does Spyre Therapeutics compare to BioNTech?

Is SYRE or BNTX more profitable?

Do analysts recommend SYRE or BNTX?

Which has more volatility & risk, SYRE or BNTX?

Does the media prefer SYRE or BNTX?

Do insiders & institutionals believe in SYRE or BNTX?

Which has better earnings & valuation, SYRE or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools